Previously, Mr King has served as the CEO of Principia Pharmaceutical, which was acquired by Human Genome Sciences, and as president of Delsys Pharmaceutical, which was acquired by Elan. Currently, he is a venture partner in Quaker BioVentures, and serves as chairman of Xencor.
Len Rosenberg, CEO of Diasome, said: “We’re excited to bring David’s invaluable experience to Diasome. He has been a part of several successful venture-backed companies in the Philadelphia region, and we know he will be an incredibly valuable asset as we embark on late-stage testing of our lead product.”